Clinical trial
A Phase III, Observer-blind, Randomized Controlled Trial to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)
NCT07017777 is registered in ClinicalTrials.gov with CanSino Biologics Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Observer-blind, Randomized Controlled Trial to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)
- Lead sponsor
- CanSino Biologics Inc.
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- November 14, 2025
- Completion date
- May 15, 2028
- Enrollment
- 600 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.